Recovery and immunogenic assessment of Orthohantavirus puumalaense N protein expressed in recombinant Escherichia coli for the treatment of HFRS

Discussions: This data is the first to suggest COVID-19 treatment with an oral antiviral can be quickly, efficiently and safely deployed in lower resourced countries.Nirmatrelvir/ritonavir appears acceptable, evidenced by high uptake and adherence.There were also no severe adverse events reported, showing the safety of the drug in a generally young but high-risk population, consistent with previous research studies.Conclusion: Programs successfully integrated their COVID-19 response into existing health service delivery infrastructure, allowing for rapid roll-out and decentralization of test and treat programs, demonstrating that introducing diagnostics and new treatment in government health systems is feasible in lower resourced settings during health emergencies.Equitable and timely access to diagnostics and treatments across the globe is crucial to combat emerging disease threats.